What is he best known for?
The fields of study he is best known for:
- Cancer
- Gene
- Internal medicine
Christos Sotiriou mostly deals with Breast cancer, Internal medicine, Oncology, Cancer and Gene expression profiling.
Christos Sotiriou interconnects Cancer research, Survival analysis, Bioinformatics and Pathology in the investigation of issues within Breast cancer.
His Cancer research research incorporates elements of Surgical oncology, DNA microarray, Gene expression, Mutation and Regulation of gene expression.
The concepts of his Oncology study are interwoven with issues in Neoadjuvant therapy, Chemotherapy, Tumor-infiltrating lymphocytes, Hazard ratio and Biomarker.
Christos Sotiriou has researched Cancer in several fields, including Genome, Immunology and Minimal residual disease.
His Gene expression profiling study combines topics from a wide range of disciplines, such as Microarray analysis techniques, Tamoxifen and Breast cancer classification.
His most cited work include:
- Breast cancer classification and prognosis based on gene expression profiles from a population-based study (1713 citations)
- International network of cancer genome projects (1611 citations)
- Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade To Improve Prognosis (1527 citations)
What are the main themes of his work throughout his whole career to date?
Christos Sotiriou spends much of his time researching Breast cancer, Internal medicine, Oncology, Cancer research and Cancer.
His Breast cancer study combines topics in areas such as Gene expression, Gene expression profiling, Bioinformatics and Pathology.
His studies deal with areas such as DNA microarray and Computational biology as well as Gene expression profiling.
His research in Chemotherapy, Trastuzumab, Clinical trial, Hazard ratio and Anthracycline are components of Internal medicine.
His Oncology research is multidisciplinary, relying on both Neoadjuvant therapy, Proportional hazards model, Gynecology and Tumor-infiltrating lymphocytes.
His Cancer research research is multidisciplinary, incorporating perspectives in Regulation of gene expression, PI3K/AKT/mTOR pathway and Immunology.
He most often published in these fields:
- Breast cancer (65.65%)
- Internal medicine (51.95%)
- Oncology (48.56%)
What were the highlights of his more recent work (between 2017-2021)?
- Breast cancer (65.65%)
- Internal medicine (51.95%)
- Oncology (48.56%)
In recent papers he was focusing on the following fields of study:
His primary areas of investigation include Breast cancer, Internal medicine, Oncology, Cancer research and Tumor-infiltrating lymphocytes.
His Breast cancer research is multidisciplinary, incorporating elements of Cancer cell and Stromal tumor.
His work is connected to Chemotherapy, Hazard ratio, Clinical trial, Confidence interval and Early breast cancer, as a part of Internal medicine.
His Oncology study integrates concerns from other disciplines, such as Odds ratio, Trastuzumab, Multivariate analysis, Adverse effect and Cohort.
Christos Sotiriou has included themes like Cancer, Metastasis, Stroma, DNA methylation and Immune system in his Cancer research study.
His Triple-negative breast cancer research includes themes of Neoadjuvant therapy and Gene expression profiling.
Between 2017 and 2021, his most popular works were:
- Pan-cancer analysis of whole genomes (538 citations)
- Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers (170 citations)
- Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis. (91 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Gene
- Internal medicine
His main research concerns Breast cancer, Internal medicine, Oncology, Cancer research and Tumor-infiltrating lymphocytes.
Christos Sotiriou studies Breast cancer, focusing on Triple-negative breast cancer in particular.
His Triple-negative breast cancer research integrates issues from Cancer immunology, Transcriptome, Nivolumab and Gene expression profiling.
His Oncology research incorporates themes from Survival rate, Multivariate analysis, Estrogen receptor, Digital polymerase chain reaction and Proportional hazards model.
His study in Cancer research is interdisciplinary in nature, drawing from both Cancer cell, Carcinogenesis, Adjuvant, Metastasis and Regulation of gene expression.
The Tumor-infiltrating lymphocytes study combines topics in areas such as Biomarker, Chemotherapy, Tumor immunology and Digital pathology.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
